Jounce Therapeutics (Nasdaq: JNCE) Jounce Therapeutics is up 84.43% premarket after Gilead Sciences (GILD) agreed to buy out the rights to Jounce's immunotherapy drug for $67 million. The deal will bolster Jounce's cash resources and Gilead will now be solely responsible for all further development and commercialization of GS-1811 globally. While it's been a tough year for the biotech stocks overall, there are still innovative companies that stand a chance for massive gains in the future. Even better – you can trade some of these companies at cheap prices. Right now our friend Alexander Green is pounding the table on a medical device company he's calling 'the biggest investment opportunity in 37 years.' Click here to learn more about this $2 company. SPI Energy Co. (Nasdaq: SPI) SPI Energy Co. is up 16.80% premarket after the global renewable energy company and provider of solar storage and electric vehicle solutions announced Solarjuice Technology, the company's solar manufacturing division, secured two provisional patents relating to a rework apparatus and another patent relating to a solar cell replacement machine. These two patents will achieve great improvements in the solar module production field. Energy stocks were among the few winners in 2022, but there could be a major change on the horizon. Due to a major mistake by Russia President Vladimir Putin, Wall Street is projecting ONE energy stock will rise from $30 to $280 in the next 18 months. Click here to unlock this energy stock. Will you be prepared for the worst in 2023? Right now analysts are calling for a 60% chance of a recession in 2023. Will your money be safe if this happens? Right now Stansberry Research is helping investors protect their assets in 2023 with their 'No. 1 Gold Play.' It's not a mining stock or ETF. It's actually a virtually unknown $6 investment. Click here to learn more about The No. 1 Gold Play. Those are the top market movers today. Happy trading! The Wake-Up Watchlist Research Team |
No comments:
Post a Comment